Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.

Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS.

Nat Commun. 2018 Jul 13;9(1):2705. doi: 10.1038/s41467-018-05030-w.

PMID:
30006619
2.

Profiles of Brain Metastases: Prioritization of Therapeutic Targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31624. [Epub ahead of print]

PMID:
29923182
3.

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT.

NPJ Precis Oncol. 2017 Sep 18;1(1):33. doi: 10.1038/s41698-017-0035-9. eCollection 2017.

4.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 May 31;173(6):1549. doi: 10.1016/j.cell.2018.05.033. Epub 2018 May 31. No abstract available.

PMID:
29856958
5.

Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era.

Barrett TF, Gill CM, Miles BA, Iloreta AMC, Bakst RL, Fowkes M, Brastianos PK, Bederson JB, Shrivastava RK.

Neurosurg Focus. 2018 Jun;44(6):E11. doi: 10.3171/2018.2.FOCUS17761.

PMID:
29852772
6.

Personalized medicine in brain metastases: a plea for more translational studies.

Ippen FM, D'Andrea M, Brastianos PK.

Per Med. 2018 May 1;15(3):141-143. doi: 10.2217/pme-2017-0087. Epub 2018 May 25. No abstract available.

7.

Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Brastianos PK, Ippen FM, Hafeez U, Gan HK.

Oncologist. 2018 Apr 27. pii: theoncologist.2017-0614. doi: 10.1634/theoncologist.2017-0614. [Epub ahead of print] Review.

PMID:
29703764
8.

Toward Precision Medicine in Brain Metastases.

Berghoff AS, Brastianos PK.

Semin Neurol. 2018 Feb;38(1):95-103. doi: 10.1055/s-0038-1627469. Epub 2018 Mar 16.

PMID:
29548056
9.

The Evolving Landscape of Brain Metastasis.

Valiente M, Ahluwalia MS, Boire A, Brastianos PK, Goldberg SB, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffietti R.

Trends Cancer. 2018 Mar;4(3):176-196. doi: 10.1016/j.trecan.2018.01.003. Epub 2018 Feb 21. Review.

PMID:
29506669
10.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 Feb 22;172(5):1050-1062.e14. doi: 10.1016/j.cell.2018.01.038. Erratum in: Cell. 2018 May 31;173(6):1549.

PMID:
29474906
11.

Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.

Juratli TA, Thiede C, Koerner MVA, Tummala SS, Daubner D, Shankar GM, Williams EA, Martinez-Lage M, Soucek S, Robel K, Penson T, Krause M, Appold S, Meinhardt M, Pinzer T, Miller JJ, Krex D, Ely HA, Silverman IM, Christiansen J, Schackert G, Wakimoto H, Kirsch M, Brastianos PK, Cahill DP.

Oncotarget. 2017 Nov 24;8(65):109228-109237. doi: 10.18632/oncotarget.22650. eCollection 2017 Dec 12.

12.

The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort.

Sun M, De Velasco G, Brastianos PK, Aizer AA, Martin A, Moreira R, Nguyen PL, Trinh QD, Choueiri TK.

Eur Urol Focus. 2018 Jan 5. pii: S2405-4569(17)30294-8. doi: 10.1016/j.euf.2017.12.007. [Epub ahead of print]

PMID:
29311016
13.

Advances in meningioma genetics: novel therapeutic opportunities.

Preusser M, Brastianos PK, Mawrin C.

Nat Rev Neurol. 2018 Feb;14(2):106-115. doi: 10.1038/nrneurol.2017.168. Epub 2018 Jan 5. Review.

PMID:
29302064
14.

Leptomeningeal metastasis from systemic cancer: Review and update on management.

Wang N, Bertalan MS, Brastianos PK.

Cancer. 2018 Jan 1;124(1):21-35. doi: 10.1002/cncr.30911. Epub 2017 Nov 22. Review.

PMID:
29165794
15.

Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.

Han CH, Brastianos PK.

Front Oncol. 2017 Sep 25;7:230. doi: 10.3389/fonc.2017.00230. eCollection 2017. Review.

16.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Zhai L, Ladomersky E, Lauing KL, Wu M, Genet M, Gritsina G, Győrffy B, Brastianos PK, Binder DC, Sosman JA, Giles FJ, James CD, Horbinski C, Stupp R, Wainwright DA.

Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

PMID:
28751450
17.

Brain Metastasis: Clinical Implications of Branched Evolution.

Dagogo-Jack I, Carter SL, Brastianos PK.

Trends Cancer. 2016 Jul;2(7):332-337. doi: 10.1016/j.trecan.2016.06.005. Epub 2016 Jun 29. Review.

PMID:
28741536
18.

Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.

Lazaro T, Brastianos PK.

CNS Oncol. 2017 Apr;6(2):139-151. doi: 10.2217/cns-2016-0038. Review.

19.

SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.

Alvarez-Breckenridge C, Brastianos PK.

Neuro Oncol. 2017 Mar 1;19(3):305-306. doi: 10.1093/neuonc/now302. No abstract available.

20.

Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.

Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, Gillespie SM, Dionne D, Luo CC, Ravichandran H, Mylvaganam R, Mount C, Onozato ML, Nahed BV, Wakimoto H, Curry WT, Iafrate AJ, Rivera MN, Frosch MP, Golub TR, Brastianos PK, Getz G, Patel AP, Monje M, Cahill DP, Rozenblatt-Rosen O, Louis DN, Bernstein BE, Regev A, Suvà ML.

Science. 2017 Mar 31;355(6332). pii: eaai8478. doi: 10.1126/science.aai8478.

21.

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.

Alvarez-Breckenridge C, Miller JJ, Nayyar N, Gill CM, Kaneb A, D'Andrea M, Le LP, Lee J, Cheng J, Zheng Z, Butler WE, Multani P, Chow Maneval E, Ha Paek S, Toyota BD, Dias-Santagata D, Santagata S, Romero J, Shaw AT, Farago AF, Yip S, Cahill DP, Batchelor TT, Iafrate AJ, Brastianos PK.

NPJ Precis Oncol. 2017 Mar 20;1(1):5. doi: 10.1038/s41698-017-0009-y. eCollection 2017.

22.

Sequencing brain metastases and opportunities for targeted therapies.

Chukwueke UN, Brastianos PK.

Pharmacogenomics. 2017 Apr;18(6):585-594. doi: 10.2217/pgs-2016-0170. Epub 2017 Mar 14. Review.

PMID:
28290769
23.

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.

Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT Jr, Cahill DP, Barker FG 2nd, Brastianos PK, Santagata S.

Neuro Oncol. 2017 Apr 1;19(4):535-545. doi: 10.1093/neuonc/now235.

24.

Novel approaches in genetic characterization and targeted therapy for brain metastases.

Castro BA, Kuang R, Brastianos PK.

Discov Med. 2016 Nov;22(122):237-250. Review.

25.

Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.

Martinez-Gutierrez JC, D'Andrea MR, Cahill DP, Santagata S, Barker FG 2nd, Brastianos PK.

Neurosurg Focus. 2016 Dec;41(6):E2. Review.

PMID:
27903124
26.

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas.

Strickland MR, Gill CM, Nayyar N, D'Andrea MR, Thiede C, Juratli TA, Schackert G, Borger DR, Santagata S, Frosch MP, Cahill DP, Brastianos PK, Barker FG 2nd.

J Neurosurg. 2017 Aug;127(2):438-444. doi: 10.3171/2016.8.JNS161076. Epub 2016 Nov 25.

PMID:
27885953
27.

Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.

Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E, Palmieri D, Liewehr DJ, Steinberg SM, Kloc W, Izycka-Swieszewska E, Duchnowska R, Nayyar N, Brastianos PK, Steeg PS, Gril B.

Clin Cancer Res. 2016 Nov 1;22(21):5287-5299. Epub 2016 May 31.

28.

Treatment of brain metastases in the modern genomic era.

Dagogo-Jack I, Gill CM, Cahill DP, Santagata S, Brastianos PK.

Pharmacol Ther. 2017 Feb;170:64-72. doi: 10.1016/j.pharmthera.2016.10.011. Epub 2016 Oct 20. Review.

PMID:
27773784
29.

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF.

J Thorac Oncol. 2016 Nov;11(11):2027-2032. doi: 10.1016/j.jtho.2016.08.126. Epub 2016 Aug 17.

30.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

31.

Landscape of Genomic Alterations in Pituitary Adenomas.

Bi WL, Horowitz P, Greenwald NF, Abedalthagafi M, Agarwalla PK, Gibson WJ, Mei Y, Schumacher SE, Ben-David U, Chevalier A, Carter S, Tiao G, Brastianos PK, Ligon AH, Ducar M, MacConaill L, Laws ER Jr, Santagata S, Beroukhim R, Dunn IF.

Clin Cancer Res. 2017 Apr 1;23(7):1841-1851. doi: 10.1158/1078-0432.CCR-16-0790. Epub 2016 Oct 5.

32.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Nigim F, Esaki S, Hood M, Lelic N, James MF, Ramesh V, Stemmer-Rachamimov A, Cahill DP, Brastianos PK, Rabkin SD, Martuza RL, Wakimoto H.

Neuro Oncol. 2016 Sep;18(9):1278-87. doi: 10.1093/neuonc/now031. Epub 2016 Mar 6.

33.

Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.

Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, Shih HA, Shaw AT.

J Thorac Oncol. 2016 Feb;11(2):256-60. doi: 10.1016/j.jtho.2015.10.010. Epub 2015 Dec 18.

34.

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S.

Neuro Oncol. 2016 May;18(5):649-55. doi: 10.1093/neuonc/nov316. Epub 2016 Jan 28.

35.

ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.

Brastianos PK, Santagata S.

Eur J Endocrinol. 2016 Apr;174(4):R139-44. doi: 10.1530/EJE-15-0957. Epub 2015 Nov 12. Review.

36.

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.

Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka DJ, Sullivan RJ, Frederick DT, Abedalthagafi M, Jones PS, Dunn IF, Nahed BV, Romero JM, Louis DN, Getz G, Cahill DP, Santagata S, Curry WT Jr, Barker FG 2nd.

J Natl Cancer Inst. 2015 Oct 23;108(2). pii: djv310. doi: 10.1093/jnci/djv310. Print 2016 Feb.

37.

BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology.

Shankar GM, Lelic N, Gill CM, Thorner AR, Van Hummelen P, Wisoff JH, Loeffler JS, Brastianos PK, Shin JH, Borges LF, Butler WE, Zagzag D, Brody RI, Duhaime AC, Taylor MD, Hawkins CE, Louis DN, Cahill DP, Curry WT, Meyerson M.

Acta Neuropathol. 2016 Jan;131(1):147-50. No abstract available.

38.

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC.

Cancer Discov. 2015 Nov;5(11):1164-1177. doi: 10.1158/2159-8290.CD-15-0369. Epub 2015 Sep 26.

39.

Rapid Intraoperative Molecular Characterization of Glioma.

Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG 2nd, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M.

JAMA Oncol. 2015 Aug;1(5):662-7. doi: 10.1001/jamaoncol.2015.0917.

40.

Genomic profiling of brain metastases: current knowledge and new frontiers.

Neagu MR, Gill CM, Batchelor TT, Brastianos PK.

Chin Clin Oncol. 2015 Jun;4(2):22. doi: 10.3978/j.issn.2304-3865.2015.06.04. Review.

41.

Management of brain metastases in the era of targeted and immunomodulatory therapies.

Brastianos PK, Cahill DP.

Oncology (Williston Park). 2015 Apr;29(4):261-3. No abstract available.

42.

Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making.

Calligaris D, Feldman DR, Norton I, Brastianos PK, Dunn IF, Santagata S, Agar NY.

Int J Mass Spectrom. 2015 Feb 1;377:690-698.

43.

PLEKHA5: A Key to Unlock the Blood-Brain Barrier?

Eisele SC, Gill CM, Shankar GM, Brastianos PK.

Clin Cancer Res. 2015 May 1;21(9):1978-80. doi: 10.1158/1078-0432.CCR-14-2604. Epub 2015 Mar 16.

44.

Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series.

Jones PS, Cahill DP, Brastianos PK, Flaherty KT, Curry WT.

Neurosurg Focus. 2015 Mar;38(3):E5. doi: 10.3171/2014.12.FOCUS14698.

PMID:
25727227
45.

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.

Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, Agar NY, Rodig SJ, Bradshaw EM, Santagata S.

Oncotarget. 2015 Mar 10;6(7):4704-16.

46.

Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.

Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP.

Acta Neuropathol Commun. 2014 Dec 24;2:167. doi: 10.1186/s40478-014-0167-x.

47.

Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, Chi AS, Shaw AT.

J Thorac Oncol. 2015 Feb;10(2):232-6. doi: 10.1097/JTO.0000000000000455.

48.

Systemic therapy of brain metastases.

Brastianos HC, Cahill DP, Brastianos PK.

Curr Neurol Neurosci Rep. 2015;15(2):518. doi: 10.1007/s11910-014-0518-9. Review.

PMID:
25492479
49.

Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5.

Abedalthagafi MS, Merrill PH, Bi WL, Jones RT, Listewnik ML, Ramkissoon SH, Thorner AR, Dunn IF, Beroukhim R, Alexander BM, Brastianos PK, Francis JM, Folkerth RD, Ligon KL, Van Hummelen P, Ligon AH, Santagata S.

Oncotarget. 2014 Nov 15;5(21):10596-606.

50.

Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.

Berghoff AS, Bartsch R, Wöhrer A, Streubel B, Birner P, Kros JM, Brastianos PK, von Deimling A, Preusser M.

Acta Neuropathol. 2014 Dec;128(6):879-91. doi: 10.1007/s00401-014-1350-7. Epub 2014 Oct 7. Review.

PMID:
25287912

Supplemental Content

Loading ...
Support Center